In light of the partial response seen of ARGX-111 in the gastric cancer patient it is of interest to notice that in this indication, responses have been observed in MET-amplified patients with several antagonists, such as the multikinase inhibitor crizotinib [29], the MET-specific kinase inhibitors AMG 337 [30] and SAR125844 [31] and the MET-targeting antibody ABT-700 [32]. The gene discussed is MET; the disease is gastric cancer.